Format

Send to

Choose Destination
Orphanet J Rare Dis. 2016 Jun 28;11(1):86. doi: 10.1186/s13023-016-0459-2.

The aggrecanopathies; an evolving phenotypic spectrum of human genetic skeletal diseases.

Author information

1
Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, NE1 3BZ, UK.
2
Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, NE1 3BZ, UK. michael.briggs@newcastle.ac.uk.
3
International Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK. michael.briggs@newcastle.ac.uk.

Abstract

The large chondroitin sulphated proteoglycan aggrecan (ACAN) is the most abundant non-collagenous protein in cartilage and is essential for its structure and function. Mutations in ACAN result in a broad phenotypic spectrum of non-lethal skeletal dysplasias including spondyloepimetaphyseal dysplasia, spondyloepiphyseal dysplasia, familial osteochondritis dissecans and various undefined short stature syndromes associated with accelerated bone maturation. However, very little is currently known about the disease pathways that underlie these aggrecanopathies, although they are likely to be a combination of haploinsufficiency and dominant-negative (neomorphic) mechanisms. This review discusses the known human and animal aggrecanopathies in the context of clinical presentation and potential disease mechanisms.

KEYWORDS:

Aggrecan; Cartilage; Chondrodysplasia; Osteochondritis dissecans; Skeletal dysplasia

PMID:
27353333
PMCID:
PMC4924316
DOI:
10.1186/s13023-016-0459-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center